How Will Pharma M&A Change In 2017?

In October 2016, US companies unleashed an unprecedented wave of deals, making it the busiest month ever for domestic M&A, despite what had been a lackluster start to the year. This momentum for M&A is expected to continue into 2017 and, according to a recent report from Deloitte, which surveyed 1,000 executives to gauge their expectations for M&A activity, the magnitude of individual transactions this year will exceed the size of deals seen in 2016.

In the report titled M&A Trends: Year-end Report 2016, Deloitte found that 75% of respondents expected deal activity to increase this year. Executives surveyed also flagged divestures as...